Literature DB >> 11438010

Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin.

O Vanhooteghem1, B Richert, M de la Brassinne.   

Abstract

Intralesional injection of bleomycin (BLM) for the treatment of warts resistant to all conventional therapies is of certain interest because of the drug's low toxicity and its efficacy. However, delayed side effects may appear, particularly Raynaud phenomenon. Accordingly, some precautions must be taken in patients with vascular or collagen diseases and, as a precaution, pregnant or lactating women and infants should not be treated with this drug.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438010     DOI: 10.1046/j.1525-1470.2001.018003249.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  4 in total

Review 1.  An armamentarium of wart treatments.

Authors:  Michelle M Lipke
Journal:  Clin Med Res       Date:  2006-12

Review 2.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

3.  Efficacy of Intralesional Bleomycin in Palmo-plantar and Periungual Warts.

Authors:  Prasoon Soni; Kanika Khandelwal; Naushin Aara; Bhikam C Ghiya; Rajesh D Mehta; Ram A Bumb
Journal:  J Cutan Aesthet Surg       Date:  2011-09

Review 4.  Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV.

Authors:  Ramya Kollipara; Erfon Ekhlassi; Christopher Downing; Jacqueline Guidry; Michael Lee; Stephen K Tyring
Journal:  J Clin Med       Date:  2015-04-24       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.